

Lawrence A Leiter

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2893346/lawrence-a-leiter-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

265
papers

31,198
citations

77
h-index

175
g-index

292
ext. papers

39,901
ext. citations

10.6
avg, IF

6.98
L-index

#	Paper	IF	Citations
265	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016 , 375, 1834-1844	59.2	2547
264	Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. <i>New England Journal of Medicine</i> , 2013 , 369, 1317-26	59.2	2459
263	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2019 , 380, 347-357	59.2	2455
262	Effects of combination lipid therapy in type 2 diabetes mellitus. <i>New England Journal of Medicine</i> , 2010 , 362, 1563-74	59.2	1940
261	Effects of dalcetrapib in patients with a recent acute coronary syndrome. <i>New England Journal of Medicine</i> , 2012 , 367, 2089-99	59.2	1424
260	SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. <i>Lancet, The</i> , 2019 , 393, 31-39	40	1300
259	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2019 , 394, 121-130	40	917
258	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2018 , 392, 1519-1529	40	771
257	Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. <i>European Heart Journal</i> , 2015 , 36, 1012-22	9.5	770
256	2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1263-1282	3.8	543
255	Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. <i>New England Journal of Medicine</i> , 2017 , 376, 1430-1440	59.2	507
254	Effect of valsartan on the incidence of diabetes and cardiovascular events. <i>New England Journal of Medicine</i> , 2010 , 362, 1477-90	59.2	493
253	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016 , 374, 2021-31	59.2	440
252	Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. <i>JAMA - Journal of the American Medical Association</i> , 2003 , 290, 502-10	27.4	408
251	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. <i>New England Journal of Medicine</i> , 2021 , 384, 117-128	59.2	408
250	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016 , 374, 2009-20	59.2	382
249	Hypertension Canada [®] 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 506-525	3.8	348

248	Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019 , 139, 2022-2031	16.7	345
247	Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 7, 611-620	18.1	330
246	Hypertension Canada [®] 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 569-88	3.8	314
245	Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 606-617	18.1	304
244	Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. <i>New England Journal of Medicine</i> , 2020 , 382, 1507-1519	59.2	302
243	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019 , 139, 2528-2536	16.7	283
242	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From an Editors' Expert Forum. <i>Diabetes Care</i> , 2018 , 41, 14-31	14.6	263
241	Postprandial glucose regulation and diabetic complications. <i>Archives of Internal Medicine</i> , 2004 , 164, 2090-5		251
240	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2021 , 384, 129-139	59.2	243
239	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. <i>Lancet</i> , 2019 , 394, 131-138	40	228
238	The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 549-68	3.8	222
237	Hypertension Canada [®] 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 557-576	3.8	205
236	Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. <i>Circulation</i> , 2019 , 140, 1693-1702	16.7	205
235	Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials. <i>European Journal of Clinical Nutrition</i> , 2014 , 68, 416-23	5.2	203
234	Effect of fructose on body weight in controlled feeding trials: a systematic review and meta-analysis. <i>Annals of Internal Medicine</i> , 2012 , 156, 291-304	8	200
233	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016 , 374, 2032-43	59.2	199
232	The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 485-501	3.8	198
231	Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2020 , 382, 1520-1530	59.2	197

230	Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. <i>Diabetes Care</i> , 2014 , 37, 2317-25	14.6	173
229	Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. <i>Diabetes Care</i> , 2015 , 38, 355-64	14.6	170
228	Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. <i>American Heart Journal</i> , 2009 , 158, 896-901.e3	4.9	166
227	The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. <i>Ophthalmology</i> , 2014 , 121, 2443-51	7.3	164
226	Ticagrelor in Patients with Stable Coronary Disease and Diabetes. <i>New England Journal of Medicine</i> , 2019 , 381, 1309-1320	59.2	156
225	Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. <i>European Heart Journal</i> , 2018 , 39, 2526-2539	9.5	156
224	Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 322, 1780-1788	27.4	155
223	Effect of fructose on glycemic control in diabetes: a systematic review and meta-analysis of controlled feeding trials. <i>Diabetes Care</i> , 2012 , 35, 1611-20	14.6	154
222	Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. <i>Atherosclerosis</i> , 2018 , 277, 195-203	3.1	147
221	Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. <i>New England Journal of Medicine</i> , 2018 , 379, 1107-1117	59.2	143
220	Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. <i>Circulation</i> , 2019 , 139, 2516-2527	16.7	142
219	Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2013 , 1, 317-28	18.1	140
218	Hypertension Canada [®] 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 596-624	3.8	139
217	The effects of fructose intake on serum uric acid vary among controlled dietary trials. <i>Journal of Nutrition</i> , 2012 , 142, 916-23	4.1	131
216	Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 306, 831-9	27.4	131
215	Inflammatory and Cholesterol Risk in the FOURIER Trial. <i>Circulation</i> , 2018 , 138, 131-140	16.7	127
214	Postprandial glucose regulation: new data and new implications. <i>Clinical Therapeutics</i> , 2005 , 27 Suppl B, S42-56	3.5	127
213	Effect of fructose on postprandial triglycerides: a systematic review and meta-analysis of controlled feeding trials. <i>Atherosclerosis</i> , 2014 , 232, 125-33	3.1	126

212	Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 42-49	6.7	121
211	Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2018 , 85, 32-37	12.7	116
210	Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. <i>Circulation</i> , 2020 , 141, 704-707	16.7	115
209	Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. <i>Journal of the American Geriatrics Society</i> , 2014 , 62, 1252-62	5.6	114
208	Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care EditorsRExpert Forum. <i>Diabetes Care</i> , 2013 , 36, 1779-88	14.6	114
207	Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2015 , 38, 696-705	14.6	114
206	Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 889-897	6.7	114
205	No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. <i>European Heart Journal</i> , 2016 , 37, 2981-2989	9.5	108
204	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. <i>Lancet, The</i> , 2019 , 394, 1169-1180	40	106
203	Effects of dietary pulse consumption on body weight: a systematic review and meta-analysis of randomized controlled trials. <i>American Journal of Clinical Nutrition</i> , 2016 , 103, 1213-23	7	106
202	Konjac-Mannan and American ginseng: emerging alternative therapies for type 2 diabetes mellitus. <i>Journal of the American College of Nutrition</i> , 2001 , 20, 370S-380S; discussion 381S-383S	3.5	102
201	Sugar-sweetened beverage consumption and incident hypertension: a systematic review and meta-analysis of prospective cohorts. <i>American Journal of Clinical Nutrition</i> , 2015 , 102, 914-21	7	99
200	Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. <i>JAMA Cardiology</i> , 2017 , 2, 370-380	16.2	98
199	Dapagliflozin® Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension. <i>Diabetes Care</i> , 2015 , 38, 1218-27	14.6	97
198	Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. <i>Circulation</i> , 2020 , 141, 1227-1234	16.7	97
197	Type 2 diabetes mellitus management in Canada: is it improving??. <i>Canadian Journal of Diabetes</i> , 2013 , 37, 82-9	2.1	92
196	Effect of tree nuts on glycemic control in diabetes: a systematic review and meta-analysis of randomized controlled dietary trials. <i>PLoS ONE</i> , 2014 , 9, e103376	3.7	90
195	The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. <i>American Heart Journal</i> , 2018 , 200, 83-89	4.9	89

194	Effect of canagliflozin on liver function tests in patients with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2016 , 42, 25-32	5.4	85
193	Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1. <i>Circulation</i> , 2018 , 138, 1304-1316	16.7	84
192	Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1781-1792	6.7	84
191	Effect of tree nuts on metabolic syndrome criteria: a systematic review and meta-analysis of randomised controlled trials. <i>BMJ Open</i> , 2014 , 4, e004660	3	83
190	DECLARE-TIMI 58: Participants Baseline characteristics. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1107-1108	11.1	80
189	High-protein diets in hyperlipidemia: effect of wheat gluten on serum lipids, uric acid, and renal function. <i>American Journal of Clinical Nutrition</i> , 2001 , 74, 57-63	7	77
188	Metabolic Surgery: Weight Loss, Diabetes, and Beyond. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 670-687	15.1	75
187	Catalytic doses of fructose may benefit glycaemic control without harming cardiometabolic risk factors: a small meta-analysis of randomised controlled feeding trials. <i>British Journal of Nutrition</i> , 2012 , 108, 418-23	3.6	75
186	The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering?. <i>Diabetes Research and Clinical Practice</i> , 2005 , 68 Suppl 2, S3-14	7.4	75
185	Effect of Fructose on Established Lipid Targets: A Systematic Review and Meta-Analysis of Controlled Feeding Trials. <i>Journal of the American Heart Association</i> , 2015 , 4, e001700	6	74
184	American ginseng improves glycemia in individuals with normal glucose tolerance: effect of dose and time escalation. <i>Journal of the American College of Nutrition</i> , 2000 , 19, 738-44	3.5	73
183	Effect of vegetarian dietary patterns on cardiometabolic risk factors in diabetes: A systematic review and meta-analysis of randomized controlled trials. <i>Clinical Nutrition</i> , 2019 , 38, 1133-1145	5.9	69
182	Day-to-day consistency in amount and source of carbohydrate intake associated with improved blood glucose control in type 1 diabetes. <i>Journal of the American College of Nutrition</i> , 1999 , 18, 242-7	3.5	64
181	Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1479-1489	6.7	63
180	Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. <i>Diabetic Medicine</i> , 2011 , 28, 1343-51	3.5	62
179	2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. <i>Canadian Journal of Cardiology</i> , 2021 , 37, 1129-1150	3.8	62
178	Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. <i>Diabetes Care</i> , 2015 , 38, 1145-53	14.6	61
177	Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. <i>Diabetes Care</i> , 2014 , 37, 2723-30	14.6	61

176	Gaps and barriers in the control of blood glucose in people with type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2017 , 14, 172-183	3.3	59
175	Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 418-435	18.1	59
174	Effect of lowering the glycemic load with canola oil on glycemic control and cardiovascular risk factors: a randomized controlled trial. <i>Diabetes Care</i> , 2014 , 37, 1806-14	14.6	59
173	Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019 , 140, 1569-1577	16.7	57
172	Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 615-28	6.7	57
171	Fructose intake and risk of gout and hyperuricemia: a systematic review and meta-analysis of prospective cohort studies. <i>BMJ Open</i> , 2016 , 6, e013191	3	53
170	Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2018 , 3, 164-168	16.2	51
169	Food sources of fructose-containing sugars and glycaemic control: systematic review and meta-analysis of controlled intervention studies. <i>BMJ, The</i> , 2018 , 363, k4644	5.9	50
168	Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. <i>Lancet Neurology, The</i> , 2020 , 19, 582-590	24.1	48
167	Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis. <i>CMAJ Open</i> , 2017 , 5, E152-E177	2.5	47
166	Effect of Replacing Animal Protein with Plant Protein on Glycemic Control in Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Nutrients</i> , 2015 , 7, 9804-24	6.7	46
165	Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. <i>JAMA Cardiology</i> , 2020 , 5, 1124-1135	16.2	46
164	Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 392, 2269-2279	4.0	46
163	Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. <i>Atherosclerosis</i> , 2007 , 194, e154-64	3.1	45
162	Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2210-2219	6.7	44
161	Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial. <i>Diabetes Care</i> , 2019 , 42, 173-176	14.6	43
160	The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 106-114	18.1	42
159	Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary). <i>Canadian Journal of Cardiology</i> , 2011 , 27, 124-31 ⁸	3.8	41

158	Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes. <i>Diabetic Medicine</i> , 2005 , 22, 963-72	3.5	40
157	Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2015 , 29, 438-44	3.2	38
156	Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial. <i>Diabetologia</i> , 2020 , 63, 698-710	10.3	38
155	Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 989-996	6.7	37
154	Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. <i>Mayo Clinic Proceedings</i> , 2020 , 95, 77-89	6.4	37
153	SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus. <i>Cell Metabolism</i> , 2019 , 30, 609-613	24.6	36
152	Cardiovascular Implications of Hypoglycemia in Diabetes Mellitus. <i>Circulation</i> , 2015 , 132, 2345-50	16.7	35
151	Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study. <i>Neurology</i> , 2019 , 92, e1435-e1446	6.5	34
150	Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. <i>Cardiovascular Diabetology</i> , 2019 , 18, 73	8.7	33
149	LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial. <i>Cardiovascular Diabetology</i> , 2016 , 15, 29	8.7	33
148	Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. <i>Diabetes Care</i> , 2020 , 43, 468-475	14.6	33
147	Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naïve patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. <i>Lancet Diabetes and Endocrinology</i> , 2013 , 1, 123-31	18.1	32
146	Simple skinfold-thickness measurements complement conventional anthropometric assessments in predicting glucose tolerance. <i>American Journal of Clinical Nutrition</i> , 2001 , 73, 567-73	7	32
145	Effect of wheat bran on serum lipids: influence of particle size and wheat protein. <i>Journal of the American College of Nutrition</i> , 1999 , 18, 159-65	3.5	32
144	Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1182-1193	15.1	31
143	Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics. <i>American Heart Journal</i> , 2018 , 203, 30-38	4.9	29
142	Dosing irregularities and self-treated hypoglycemia in type 2 diabetes: results from the Canadian cohort of an international survey of patients and healthcare professionals. <i>Canadian Journal of Diabetes</i> , 2014 , 38, 38-44	2.1	29
141	The effect of a dietary portfolio compared to a DASH-type diet on blood pressure. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2015 , 25, 1132-9	4.5	28

140	The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents. <i>Diabetes Research and Clinical Practice</i> , 2018 , 143, 1-14	7.4	28
139	Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. <i>American Journal of Medicine</i> , 2016 , 129, 340.e1-8	2.4	27
138	Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 880-893	18.1	27
137	Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials. <i>Diabetic Medicine</i> , 2018 , 35, 121-130	3.5	26
136	Residual cardiovascular risk among people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21 Suppl 1, 28-38	6.7	25
135	Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions. <i>Circulation</i> , 2020 , 141, 843-862	16.7	25
134	Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. <i>Journal of Clinical Lipidology</i> , 2020 , 14, 649-659.e6	4.9	24
133	Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1. <i>Cardiovascular Research</i> , 2021 , 117, 284-291	9.9	23
132	Relation of Total Sugars, Sucrose, Fructose, and Added Sugars With the Risk of Cardiovascular Disease: A Systematic Review and Dose-Response Meta-analysis of Prospective Cohort Studies. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 2399-2414	6.4	22
131	Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 311-8	3.8	21
130	Cardiovascular Risk Factors and In-hospital Mortality in Acute Coronary Syndromes: Insights From the Canadian Global Registry of Acute Coronary Events. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 1455-61	3.8	21
129	Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. <i>Cardiovascular Diabetology</i> , 2017 , 16, 70	8.7	21
128	Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. <i>Circulation</i> , 2019 , 139, 366-375	16.7	21
127	Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. <i>Circulation</i> , 2018 , 138, 1605-1607	16.7	20
126	Association of Major Food Sources of Fructose-Containing Sugars With Incident Metabolic Syndrome: A Systematic Review and Meta-analysis. <i>JAMA Network Open</i> , 2020 , 3, e209993	10.4	20
125	The effect of small doses of fructose and allulose on postprandial glucose metabolism in type 2 diabetes: A double-blind, randomized, controlled, acute feeding, equivalence trial. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2361-2370	6.7	20
124	Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. <i>Clinical Cardiology</i> , 2019 , 42, 498-505	3.3	19
123	Diabetes for Cardiologists: Practical Issues in Diagnosis and Management. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 366-377	3.8	19

122	Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 766-74	6.7	19
121	Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study). <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 663-70	6.7	19
120	CANTOS Ushers in a New Calculus of Inflammasome Targeting for Vascular Protection-and Maybe More. <i>Cell Metabolism</i> , 2017 , 26, 703-705	24.6	18
119	Lifestyle modifications to prevent and control hypertension. 2. Recommendations on obesity and weight loss. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. <i>Cmaj</i> , 1999 , 160, 87-12	3.5	18
118	Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease. <i>JACC: Cardiovascular Imaging</i> , 2021 , 14, 1164-1173	8.4	18
117	Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 186-90	6.7	18
116	The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes. <i>Canadian Journal of Diabetes</i> , 2015 , 39 Suppl 5, S167-75	2.1	17
115	Impact of baseline glycosylated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1700-1704	6.7	16
114	Efficacy and Safety of Degludec Compared to Glargine 300 Units/mL in Insulin-Experienced Patients With Type 2 Diabetes: Trial Protocol Amendment (NCT03078478). <i>Journal of Diabetes Science and Technology</i> , 2019 , 13, 498-506	4.1	16
113	The Effect of Liquid Meal Replacements on Cardiometabolic Risk Factors in Overweight/Obese Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Diabetes Care</i> , 2019 , 42, 767-776	14.6	16
112	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE): 2014 update. <i>Cmaj</i> , 2014 , 186, 1299-305	3.5	16
111	Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58. <i>European Journal of Heart Failure</i> , 2021 , 23, 1026-1036	12.3	16
110	Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. <i>Circulation</i> , 2020 , 142, 734-747	16.7	16
109	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update. <i>Cmaj</i> , 2018 , 190, E1192-E1206	3.5	16
108	Effectiveness of gliclazide MR 60mg in the management of type 2 diabetes: analyses from the EASYDia trial. <i>Diabetology and Metabolic Syndrome</i> , 2018 , 10, 30	5.6	15
107	Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials. <i>Diabetic Medicine</i> , 2018 , 35, 1742-1751	3.5	14
106	Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2389-2398	6.7	14
105	Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada. <i>Pharmacoeconomics - Open</i> , 2019 , 3, 537-550	2.1	13

104	Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1122-1131	6.7	13
103	Dalceptrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. <i>Diabetes Care</i> , 2020 , 43, 1077-1084	14.6	13
102	Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1357-1368	6.7	13
101	Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. <i>Cardiovascular Diabetology</i> , 2019 , 18, 149	8.7	13
100	Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1594-1601	6.7	12
99	Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial. <i>Diabetes and Metabolism</i> , 2017 , 43, 453-459	5.4	12
98	The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardiLink-6 trial. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 895-897	4.3	12
97	Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol. <i>Cardiovascular Diabetology</i> , 2020 , 19, 14	8.7	12
96	Insights Into the Current Management of Older Adults With Type 2 Diabetes in the Ontario Primary Care Setting. <i>Canadian Journal of Diabetes</i> , 2018 , 42, 23-30	2.1	12
95	Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimpiride in Patients with Type 2 Diabetes on Metformin. <i>Diabetes Therapy</i> , 2016 , 7, 269-78	3.6	12
94	Glycaemic control and cardiovascular risk factor management in patients with diabetes with and without coronary artery disease: insights from the diabetes mellitus status in Canada survey. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2016 , 2, 277-284	4.6	12
93	The Effect of Small Doses of Fructose and Its Epimers on Glycemic Control: A Systematic Review and Meta-Analysis of Controlled Feeding Trials. <i>Nutrients</i> , 2018 , 10,	6.7	12
92	Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1506-1512	6.7	11
91	The clinical burden of type 2 diabetes in patients with acute coronary syndromes: prognosis and implications for short- and long-term management. <i>Diabetes and Vascular Disease Research</i> , 2014 , 11, 395-409	3.3	11
90	A comparison of the assessment and management of cardiometabolic risk in patients with and without type 2 diabetes mellitus in Canadian primary care. <i>Diabetes, Obesity and Metabolism</i> , 2013 , 15, 1093-100	6.7	11
89	Can thiazolidinediones delay disease progression in type 2 diabetes?. <i>Current Medical Research and Opinion</i> , 2006 , 22, 1193-201	2.5	11
88	Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2487-2492	6.7	11
87	Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 29-38	6.7	11

86	The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. <i>Diabetes Care</i> , 2021 , 44, 1805-1815	14.6	10
85	Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis. <i>Metabolism Open</i> , 2020 , 7, 100039	2.8	9
84	Identification of educational needs in the management of overweight and obesity: results of an international survey of attitudes and practice. <i>Clinical Obesity</i> , 2015 , 5, 245-55	3.6	9
83	Optimal care of cardiovascular disease and type 2 diabetes patients: shared responsibilities between the cardiologist and diabetologist. <i>Atherosclerosis Supplements</i> , 2006 , 7, 37-42	1.7	9
82	Blood Pressure Management in Adults With Type 2 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey. <i>Canadian Journal of Diabetes</i> , 2018 , 42, 130-137	2.1	8
81	Safety and efficacy of linagliptin in patients with type 2 diabetes mellitus and coronary artery disease: Analysis of pooled events from 19 clinical trials. <i>Journal of Diabetes and Its Complications</i> , 2016 , 30, 1378-84	3.2	8
80	Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation. <i>Diabetes Research and Clinical Practice</i> , 2016 , 112, 50-56	7.4	8
79	Effects of Changing the Amount and Source of Dietary Carbohydrates on Symptoms and Dietary Satisfaction Over a 1-Year Period in Subjects with Type 2 Diabetes: Canadian Trial of Carbohydrates in Diabetes (CCD). <i>Canadian Journal of Diabetes</i> , 2017 , 41, 164-176	2.1	8
78	Use of bioelectrical impedance analysis measurements in patients with diabetes. The Diabetes Control and Complications Trial Research Group. <i>American Journal of Clinical Nutrition</i> , 1996 , 64, 515S-518S	7.8	8
77	From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2021 , 20, 92	8.7	8
76	Gastrointestinal safety across the albiglutide development programme. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 930-5	6.7	8
75	The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1020-1029	6.7	8
74	Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: Results over 52 weeks. <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 1283-1285	3.2	7
73	Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53. <i>Clinical Chemistry</i> , 2019 , 65, 781-790	5.5	7
72	The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1690-1695	6.7	7
71	Profile of adults with type 2 diabetes and uptake of clinical care best practices: results from the 2011 Survey on Living with Chronic Diseases in Canada - Diabetes component. <i>Diabetes Research and Clinical Practice</i> , 2014 , 103, 11-9	7.4	7
70	Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. <i>European Heart Journal</i> , 2021 , 42, 2565-2573	9.5	7
69	Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. <i>Diabetes Care</i> , 2021 , 44, 1159-1167	14.6	7

68	Secondary Prevention Beyond Hospital Discharge for Acute Coronary Syndrome: Evidence-Based Recommendations. <i>Canadian Journal of Cardiology</i> , 2016 , 32, S15-34	3.8	7
67	Latest Evidence on Sulfonylureas: What's New?. <i>Diabetes Therapy</i> , 2020 , 11, 15-22	3.6	7
66	Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2058-2066	6.7	6
65	Glycated Hemoglobin Level Goal Achievement in Adults With Type 2 Diabetes in Canada: Still Room for Improvement. <i>Canadian Journal of Diabetes</i> , 2019 , 43, 384-391	2.1	6
64	Use of GLP-1 RAs in Cardiovascular Disease Prevention: A Practical Guide. <i>Circulation</i> , 2018 , 137, 2200-2207	2.7	6
63	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial. <i>Annals of Internal Medicine</i> , 2021 , 174, 1065-1072	8	6
62	A randomized trial of icosapent ethyl in ambulatory patients with COVID-19. <i>iScience</i> , 2021 , 24, 103040	6.1	6
61	Effects of L-Tryptophan on Food Intake and Selection in Lean Men and Women. <i>Annals of the New York Academy of Sciences</i> , 2006 , 499, 327-328	6.5	5
60	Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?. <i>Clinical Diabetes</i> , 2019 , 37, 316-337	2.9	5
59	A Practical Guide to the Use of Glucose-Lowering Agents With Cardiovascular Benefit or Proven Safety. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 940-942	3.8	4
58	Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial. <i>ESC Heart Failure</i> , 2021 , 8, 2603-2607	3.7	4
57	Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 , 6, 801-810	16.2	4
56	From hyperglycemia to the risk of cardiovascular disease. <i>Reviews in Cardiovascular Medicine</i> , 2006 , 7 Suppl 2, S3-9	3.9	4
55	4945Inclisiran-mediated reductions in Lp(a) in the ORION-1 trial. <i>European Heart Journal</i> , 2019 , 40,	9.5	3
54	Attainment of Canadian and European guidelines lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin. <i>International Journal of Clinical Practice</i> , 2010 , 64, 1765-72	2.9	3
53	Diabetic dyslipidaemia: effective management reduces cardiovascular risk. <i>Atherosclerosis Supplements</i> , 2005 , 6, 37-43	1.7	3
52	Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial. <i>American Heart Journal</i> , 2020 , 221, 60-66	4.9	3
51	Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis. <i>Cardiovascular Diabetology</i> , 2020 , 19, 199	8.7	3

50	Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. <i>European Heart Journal</i> , 2021 , 42, 2995-3007	9.5	3
49	Low-glycaemic index diet to improve glycaemic control and cardiovascular disease in type 2 diabetes: design and methods for a randomised, controlled, clinical trial. <i>BMJ Open</i> , 2016 , 6, e012220	3	3
48	Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials. <i>Diabetic Medicine</i> , 2020 , 37, 256-266	3.5	3
47	Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	2
46	Cross-sectional associations between dietary intake and carotid intima media thickness in type 2 diabetes: baseline data from a randomised trial. <i>BMJ Open</i> , 2017 , 7, e015026	3	2
45	GOAL Canada: Physician Education and Support Can Improve Patient Management. <i>CJC Open</i> , 2020 , 2, 49-54	2	2
44	CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 1350-1361	3.8	2
43	Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment - a clinical appraisal. <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 1451-1457	3.2	2
42	Dosing irregularities and self-treated hypoglycemia in type 2 diabetes: results from the Canadian Cohort of an International Survey of Patients and Healthcare Professionals. <i>Canadian Journal of Diabetes</i> , 2015 , 39 Suppl 4, 19-25	2.1	2
41	The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.9	2
40	1021-P: HbA1c Levels and Rates of Hypoglycemia with Insulin Degludec U200 and Insulin Glargine U300 Stratified by Renal Function Subgroups: Post Hoc Analysis from the CONCLUDE Trial. <i>Diabetes</i> , 2020 , 69, 1021-P	0.9	2
39	Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020 , 26, 143-153	1.9	2
38	Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 2366-2377	15.1	2
37	Different Food Sources of Fructose-Containing Sugars and Fasting Blood Uric Acid Levels: A Systematic Review and Meta-Analysis of Controlled Feeding Trials. <i>Journal of Nutrition</i> , 2021 , 151, 2409-2421	4.1	2
36	Co-administration of viscous fiber, Salba-chia and ginseng on glycemic management in type 2 diabetes: a double-blind randomized controlled trial. <i>European Journal of Nutrition</i> , 2021 , 60, 3071-3083	5.2	2
35	Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 1345-1351	5.6	2
34	Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 484-490	18.1	2
33	How to reach LDL targets quickly in patients with diabetes or metabolic syndrome. <i>Journal of Family Practice</i> , 2008 , 57, 661-8	0.2	2

32	A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings.. <i>Journal of Diabetes Science and Technology</i> , 2022 , 19322968221085273		
31	Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 1663-1674	3.9	1
30	Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data. <i>Clinical Diabetes and Endocrinology</i> , 2020 , 6, 2	4.7	1
29	Questioning the safety and benefits of evolocumab - AuthorsReply. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 11-12	18.1	1
28	Effects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE-3 Trial. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	1
27	PROVE-IT proved it: lower is better--pro. <i>Canadian Journal of Cardiology</i> , 2006 , 22 Suppl B, 91B-94B	3.8	1
26	Rosuvastatin 2004 , 2, 41-55		1
25	Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58.. <i>Diabetes Care</i> , 2022 , 45, e27-e29	14.6	1
24	The use of bioelectrical impedance analysis (BIA) to estimate body composition in the Diabetes Control and Complications Trial (DCCT) 1994 , 18, 829-35		1
23	Alirocumab efficacy and safety by body mass index: A pooled analysis from 10 Phase 3 ODYSSEY trials. <i>Diabetes and Metabolism</i> , 2020 , 46, 280-287	5.4	1
22	Does management of lipid lowering differ between specialists and primary care: Insights from GOAL Canada. <i>International Journal of Clinical Practice</i> , 2021 , 75, e13861	2.9	1
21	Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial. <i>Stroke</i> , 2021 , 52, 2494-2501	6.7	1
20	Association of Low- and No-Calorie Sweetened Beverages as a Replacement for Sugar-Sweetened Beverages With Body Weight and Cardiometabolic Risk: A Systematic Review and Meta-analysis.. <i>JAMA Network Open</i> , 2022 , 5, e222092	10.4	1
19	Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome. <i>CJC Open</i> , 2020 , 2, 402-415	2	0
18	Incidence of Myocardial Infarction Types in Patients Treated With Ticagrelor in the THEMIS Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021 , CIRCINTERVENTIONS120011035	6	0
17	Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 ,	6.7	0
16	Validating the NIH LDL-C equation in a specialized lipid cohort: Does it add up?. <i>Clinical Biochemistry</i> , 2021 , 99, 60-60	3.5	0
15	Tree nuts improve criteria of the metabolic syndrome: a systematic review and meta-analysis of randomized controlled dietary trials (1025.6). <i>FASEB Journal</i> , 2014 , 28, 1025.6	0.9	0

14	A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. <i>Diabetes Care</i> , 2021 , 44, 2573-2581	14.6	o
13	Balance of Benefit and Risk of Ticagrelor in Patients With Diabetes and Stable Coronary Artery Disease According to Bleeding Risk Assessment With the CRUSADE Score: Data From THEMIS and THEMIS PCI: Abbreviated title: Bleeding risk stratification of ticagrelor.. <i>American Heart Journal</i> , 2022 , 163, 100-107	4.9	o
12	A Web-Based Health Application to Translate Nutrition Therapy for Cardiovascular Risk Reduction in Primary Care (PortfolioDiet.app): Quality Improvement and Usability Testing Study.. <i>JMIR Human Factors</i> , 2022 , 9, e34704	2.5	o
11	Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6.. <i>Stroke</i> , 2022 , 101161STROKEAHA121037775	6.7	o
10	Correctly understanding the diabetes data in FOURIER. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2342-2343	6.7	o
9	Diagnosis of coronary artery disease in the diabetic patient. <i>Canadian Journal of Cardiology</i> , 2006 , 22 Suppl A, 7A-8A	3.8	
8	Response to the Letter on "The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus".. <i>Cardiovascular Drugs and Therapy</i> , 2022 , 1	3.9	
7	Long Term Effectiveness of A Dietary Portfolio of Cholesterol-Lowering Foods in Hypercholesterolemic Subjects. <i>FASEB Journal</i> , 2008 , 22, 460.8	0.9	
6	Effect of tree nuts on glycemic control in diabetes: a systematic review and meta-analysis of randomized controlled dietary trials (1025.16). <i>FASEB Journal</i> , 2014 , 28, 1025.16	0.9	
5	Tree Nuts Improve Glycemic Control: A Systematic Review and Meta-Analysis of Randomized Controlled Dietary Trials. <i>FASEB Journal</i> , 2015 , 29, 383.1	0.9	
4	Effect of a Low Glycemic Index Diet on Markers of Oxidative Damage in Type 2 Diabetes. <i>FASEB Journal</i> , 2015 , 29, 274.5	0.9	
3	Cardiovascular risk factor management in patients with diabetes: Does management differ with disease duration?. <i>Journal of Diabetes and Its Complications</i> , 2021 , 35, 107997	3.2	
2	Estrogens are indicated for the prevention of coronary artery disease: a debate for estrogen. <i>Canadian Journal of Cardiology</i> , 2000 , 16 Suppl E, 13E-16E	3.8	
1	Case 1. Cardiovascular dysfunction syndrome. <i>Canadian Journal of Cardiology</i> , 2000 , 16 Suppl E, 21E-23E	3.8	